Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease risk » increased risk (Expand Search), increases risk (Expand Search), disease risk (Expand Search)
mean decrease » a decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 61 - 80 results of 22,987 for search '(( significant decrease risk ) OR ( significant ((mean decrease) OR (teer decrease)) ))', query time: 0.78s Refine Results
  1. 61
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 62
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 63
    Mean values of physical parameters of rock samples.

    Mean values of physical parameters of rock samples. by Dengke Yang (842532)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by gender (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by gender (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 65
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test by gender (<i>n</i> = 900).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test by gender (<i>n</i> = 900). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 66
    Bias risk assessments for each RCT study.

    Bias risk assessments for each RCT study. by Xin Liu (43569)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Bias risk assessments for each RCS study.

    Bias risk assessments for each RCS study. by Xin Liu (43569)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test by age groups (<i>n</i> = 900).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test by age groups (<i>n</i> = 900). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 69
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by age group (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by age group (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 70
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: